Department of Orthopedics, School of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Division of Orthodontics, Department of Developmental and Surgical Services, Institute for Virology, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA.
Int J Mol Sci. 2021 Sep 8;22(18):9702. doi: 10.3390/ijms22189702.
Prior work demonstrated that Phlpp1 deficiency alters trabecular bone mass and enhances M-CSF responsiveness, but the cell types and requirement of Phlpp1 for this effect were unclear. To understand the function of Phlpp1 within myeloid lineage cells, we crossed floxed mice with mice harboring LysM-Cre. Micro-computed tomography of the distal femur of 12-week-old mice revealed a 30% increase in bone volume per total volume of female conditional knockouts, but we did not observe significant changes within male Phlpp1 cKO mice. Bone histomorphmetry of the proximal tibia further revealed that Phlpp1 cKO females exhibited elevated osteoclast numbers, but conversely had reduced levels of serum markers of bone resorption as compared to littermate controls. Osteoblast number and serum markers of bone formation were unchanged. In vitro assays confirmed that ablation enhanced osteoclast number and area, but limited bone resorption. Additionally, reconstitution with exogenous Phlpp1 suppressed osteoclast numbers. Dose response assays demonstrated that cells are more responsive to M-CSF, but reconstitution with Phlpp1 abrogated this effect. Furthermore, small molecule-mediated Phlpp inhibition enhanced osteoclast numbers and size. Enhanced phosphorylation of Phlpp substrates-including Akt, ERK1/2, and PKCζ-accompanied these observations. In contrast, actin cytoskeleton disruption occurred within Phlpp inhibitor treated osteoclasts. Moreover, Phlpp inhibition reduced resorption of cells cultured on bovine bone slices in vitro. Our results demonstrate that deficiency within myeloid lineage cells enhances bone mass by limiting bone resorption while leaving osteoclast numbers intact; moreover, we show that Phlpp1 represses osteoclastogenesis and controls responses to M-CSF.
先前的工作表明,Phlpp1 缺失会改变小梁骨量并增强 M-CSF 的反应性,但细胞类型和 Phlpp1 发挥此作用的要求尚不清楚。为了了解 Phlpp1 在髓系细胞中的功能,我们将 floxed 小鼠与携带 LysM-Cre 的小鼠进行了杂交。12 周龄雌性条件性敲除小鼠的远端股骨 micro-CT 显示骨体积/总体积增加了 30%,但未观察到雄性 Phlpp1 cKO 小鼠有明显变化。胫骨近端的骨组织形态计量学进一步显示,Phlpp1 cKO 雌性的破骨细胞数量增加,但与同窝对照相比,血清骨吸收标志物水平降低。成骨细胞数量和血清骨形成标志物没有变化。体外实验证实,Phlpp1 缺失增强了破骨细胞数量和面积,但限制了骨吸收。此外,外源性 Phlpp1 的再构成抑制了破骨细胞数量。剂量反应实验表明,Phlpp1 缺失的细胞对 M-CSF 的反应更敏感,但 Phlpp1 的再构成消除了这种效应。此外,小分子介导的 Phlpp 抑制增强了破骨细胞的数量和大小。这些观察结果伴随着 Phlpp 底物的增强磷酸化,包括 Akt、ERK1/2 和 PKCζ。相比之下,Phlpp 抑制剂处理的破骨细胞中发生了肌动蛋白细胞骨架破坏。此外,Phlpp 抑制减少了体外培养在牛骨切片上的细胞的吸收。我们的结果表明,髓系细胞中 Phlpp1 的缺失通过限制骨吸收来增强骨量,同时保持破骨细胞数量不变;此外,我们表明 Phlpp1 抑制破骨细胞生成并控制对 M-CSF 的反应。